The Drug Enforcement Administration (DEA) is arguing that a federal law giving seriously ill people the \u201cright to try\u201d investigational drugs doesn\u2019t apply to controlled substances like psychedelics. The agency\u2019s claim comes in a new brief in a lawsuit filed by a Washington State doctor seeking to legally use psilocybin to treat cancer patients in end-of-life care.<\/p>\n
\u201cBecause substances in Schedule I are deemed to have no accepted medical use in under the CSA,\u201d DEA contends, referring to the federal Controlled Substances Act (CSA), \u201cthe law does not provide for any registration that would permit such drugs to be dispensed in the course of professional practice.\u201d<\/p>\n
DEA filed the brief late last week in U.S. Circuit Court of Appeals for the Ninth Circuit, in response to the latest legal challenge from Dr. Sunil Aggarwal and the Advanced Integrative Medical Science (AIMS) Institute<\/a>. Aggarwal and AIMS have spent years pursuing various legal and regulatory pathways to allow the clinic to use psilocybin in palliative care<\/a>.<\/p>\n The clinic generally argues that the CSA must accommodate a path to legally accessing psilocybin under state and federal right to try (RTT) laws, which are intended to give patients with terminal conditions the opportunity to try investigational medications that have not been approved for general use.<\/p>\n Washington State adopted a right to try law in 2017, and then-President Donald Trump (R) signed the federal Right to Try Act<\/a> the following year. Dozens of other states have also enacted right to try policies.<\/p>\n In the years since, AIMS has presented DEA with multiple proposals in order either to legally cultivate or otherwise obtain psilocybin to treat patients under RTT. The agency has denied them all.<\/p>\n \u201cDEA has rejected each request,\u201d the clinic argued in its opening brief earlier this year, \u201cbut has never addressed the arguments that Dr. Aggarwal has raised in support of them.\u201d<\/p>\n \u201cIf DEA wants to disclaim authority to grant Dr. Aggarwal access to psilocybin under the CSA and RTT,\u201d AIMS contined, \u201cit must provide a reasoned explanation for how that decision comports with the CSA and the agency\u2019s own precedent.\u201d<\/p>\n Eight U.S. states as well as Washington, D.C. have filed a friend of the court brief in support of AIMS\u2019s effort to use psilocybin under state and federal RTT laws.<\/p>\n But in its response this week, DEA asserts that the federal RTT Act doesn\u2019t affect CSA\u2019s prohibition of certain drugs.<\/p>\n \u201cThe Right to Try Act does not provide anyone with a right to dispense or receive controlled substances,\u201d the new brief says. Rather, the primary function of the federal law was \u201cto relieve qualifying individuals from regulatory requirements that would otherwise be imposed on eligible investigational drugs under the\u201d federal Food, Drug and Cosmetics Act (FDCA), DEA argues.<\/p>\n \u201cAs DEA explained, the Right to Try Act does not \u2018provide any exemptions from the CSA or its implementing regulations. And it does not \u2018give the DEA authority to waive CSA requirements,’\u201d the government\u2019s brief says. \u201cIndeed, the Right to Try Act does not even mention the CSA or controlled substances at all.\u201d<\/p>\n If Aggarwal wants to give psilocybin to patients, DEA contends he would need to be a registered researcher conducting an approved project\u2014which DEA says are matters handled by different federal agencies.<\/p>\n \u201cThe only registration that would permit a physician to dispense a schedule I controlled substance is registration as a researcher conducting an approved research project,\u201d its brief says. \u201cDEA cannot issue such a registration unless the Secretary of Health and Human Services, acting through FDA, determines that the research protocol is meritorious and the applicant is qualified and competent to conduct it.\u201d<\/p>\n DEA\u2019s brief criticizes the AIMS lawsuit\u2019s interpretation of the law as \u201ca fundamental misunderstanding\u201d and \u201ca tortuous account of the interaction between the two statutes\u201d\u2014RTT and FDCA. Such a reading, it says, \u201cwould vest authority in DEA to allow physicians to provide patients with schedule I substances for therapeutic purposes, notwithstanding Congress\u2019s determination that the drugs lack accepted medical use or safety under medical supervision.\u201d<\/p>\n \u201cPetitioners\u2019 posited tensions between the CSA and the FDCA are without basis,\u201d the agency\u2019s brief says. \u201cWhile the subject matter of the two statutes overlaps somewhat (because they both deal with drugs), each statute establishes its own requirements and prohibitions, and DEA and FDA have complementary spheres of authority\u2026 But that does not mean that one agency has superseded or interfered with the other\u2019s statutory regime.\u201d<\/p>\n A 2022 amendment to the federal RTT Act created a separate registration process to facilitate cannabis research, DEA noted in its brief, but \u201cthis new process still requires that new research projects be \u2018reviewed and allowed\u2026by the Secretary of Health and Human Services.’\u201d<\/p>\n \u201cThus,\u201d the filing says, \u201ceven when Congress has acted specifically to enhance research of a Schedule I drug, it has made researcher registration conditional on approval by the Secretary.\u201d<\/p>\n Shortly after the lawsuit was filed, Washington State and eight other jurisdictions\u2014Delaware, Illinois, Michigan, Minnesota, Nevada, Oregon, Pennsylvania and Washington, D.C.\u2014filed an amicus brief<\/a> in support of the clinic\u2019s position, arguing that CSA doesn\u2019t prohibit the use of controlled substances under RTT. Many of the same states filed an amicus brief in a related 2021 case involving Aggarwal<\/a>.<\/p>\n \u201cThe CSA was intended to combat drug trafficking and abuse,\u201d says the latest filing, led by the office of Washington State Attorney General Bob Ferguson (D).<\/p>\n \u201cIt is easy to make sense of both the CSA and the later, more specific RTT Act,\u201d it suggests: \u201cneither law facilitates traffic in illicit substances, both laws emphasize the primacy of states in the regulation of medical practice, and the RTT Act includes broad immunity from liability.\u201d<\/p>\n \u201cIt is irrelevant whether a Schedule I substance has a \u2018currently accepted medical use\u2019 under the CSA in the context of uses authorized by the RTT Act,\u201d the states\u2019 brief says. \u201cThe RTT Act\u2019s purpose is to provide a unique, targeted exemption from such requirements.\u201d<\/p>\n Aggarwal and AIMS have been working since at least 2020 to find a way to legally obtain psilocybin for patients in palliative care, initially seeking to win permission from regulators under state and federal RTT laws<\/a>.<\/p>\n When DEA rebuffed that request, Aggarwal sued. But in early 2022, a federal appellate panel\u00a0dismissed the lawsuit, opining that the court lacked jurisdiction<\/a>\u00a0because DEA\u2019s rejection of Aggarwal\u2019s administrative request didn\u2019t constitute a reviewable agency action.<\/p>\n The current Ninth Circuit cases stems from Aggarwal\u2019s responses to that ruling. In February 2022, the doctor filed a formal petition with DEA to reschedule psilocybin from Schedule I to Schedule II under the federal Controlled Substances Act (CSA)\u2014the denial of which\u00a0is\u00a0<\/em>a reviewable action. He also applied for the regulatory waiver to obtain psilocybin.<\/p>\n DEA denied Aggarwal\u2019s petition in September 2022 and rejected the waiver request the next month. The doctor\u2019s Ninth Circuit cases challenge both decisions.<\/p>\n As Aggarwal\u2019s efforts have made its way through the courts, a number of studies have strengthened the case for psilocybin\u2019s legitimate medical use. In response, Congress late last year sent a defense bill to President Joe Biden (D) that contains provisions to\u00a0fund studies into the therapeutic use of psychedelics such as psilocybin and MDMA<\/a>\u00a0for military service members.<\/p>\n A recent clinical trial published by the American Medical Association, meanwhile, found that psilocybin\u00a0\u201cdisplayed strong and persistent antidepressant effects\u201d in people with bipolar II disorder<\/a>, \u201cwith no signal of worsening mood instability or increased suicidality.\u201d<\/p>\n In September of last year, researchers at Johns Hopkins and Ohio State universities published a report that\u00a0linked psilocybin use with \u201cpersisting reductions\u201d in depression, anxiety and alcohol misuse<\/a>, as well as increases in emotional regulation, spiritual wellbeing and extraversion.<\/p>\n Those results were \u201chighly consistent with a growing body of clinical trial, behavioral pharmacology, and epidemiological data on psilocybin,\u201d authors of the study said. \u201cOverall, these data provide an important window into the current resurgence of public interest in classic psychedelics and the outcomes of contemporaneous increases in naturalistic psilocybin use.\u201d<\/p>\n Last August,\u00a0a separate study from the American Medical Association (AMA)<\/a>\u00a0found that people with major depression experienced \u201cclinically significant sustained reduction\u201d in their symptoms after just one dose of psilocybin.<\/p>\n And a survey by Canadian researchers published in October said psilocybin use\u00a0can help ease psychological distress in people who had adverse experiences as children<\/a>. Researchers said psilocybin appeared to offer \u201cparticularly strong benefits to those with more severe childhood adversity.\u201d<\/p>\n Canada, for its part, allowed four cancer patients in 2020\u00a0to become the nation\u2019s first people in decades to legally possess psilocybin<\/a>\u00a0after being granted permission by the country\u2019s health minister to use the substance for end-of-life care. Later that year, some healthcare professionals\u00a0also gained the ability to legally possess and use psilocybin themselves<\/a>.<\/p>\n A survey published earlier this year found that roughly\u00a08 in 10 Canadians believe psilocybin is \u201ca reasonable choice\u201d<\/a>\u00a0for end-of-life care.<\/p>\n Read the DEA response brief<\/a> in AIMS v. DEA<\/em> below:<\/strong><\/p>\n\n Second California Senate Committee Approves Bill To Legalize Psychedelic Service Centers<\/a><\/p>\n<\/blockquote>\n\n Photo courtesy of Wikimedia\/Workman<\/a>.<\/em><\/p>\n The post In Case On Psilocybin Access For Cancer Patients, DEA Says Federal Right To Try Law \u2018Does Not Provide Any Exemptions\u2019 From Controlled Substance Act<\/a> appeared first on Marijuana Moment<\/a>.<\/p>\n
The Drug Enforcement Administration (DEA) is arguing that a federal law giving seriously ill people the \u201cright to try\u201d investigational drugs doesn\u2019t apply to controlled substances like psychedelics. The agency\u2019s claim comes in a new brief in a lawsuit filed by a Washington State doctor seeking to legally use psilocybinContinue Reading<\/a><\/span><\/p>\n","protected":false},"author":24,"featured_media":0,"comment_status":"false","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[18,81],"tags":[],"_links":{"self":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts\/74527"}],"collection":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/comments?post=74527"}],"version-history":[{"count":1,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts\/74527\/revisions"}],"predecessor-version":[{"id":74528,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts\/74527\/revisions\/74528"}],"wp:attachment":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/media?parent=74527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/categories?post=74527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/tags?post=74527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n
\nRead More: In Case On Psilocybin Access For Cancer Patients, DEA Says Federal Right To Try Law \u2018Does Not Provide Any Exemptions\u2019 From Controlled Substance Act<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"